Sgnlva-005: Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies

被引：0
|
作者：
Anderson, Ian Churchill
Wang, Yinghui
Wang, Zejing
Sanborn, Rachel E.
机构：
[1] St Joseph Heritage Healthcare, Santa Rosa, CA USA
[2] Seattle Genet Inc, Bothell, WA USA
[3] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS469
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
    Finn, Richard S.
    Kang, Yoon-Koo
    Mulcahy, Mary
    Polite, Blase N.
    Lim, Ho Yeong
    Walters, Ian
    Baudelet, Christine
    Manekas, Demetrios
    Park, Joong-Won
    CLINICAL CANCER RESEARCH, 2012, 18 (07) : 2090 - 2098
  • [32] An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma
    Eisen, T.
    Marais, R.
    Affolter, A.
    Lorigan, P.
    Ottensmeier, C.
    Robert, C.
    Corrie, P.
    Chevreau, C.
    Erlandsson, F.
    Gore, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
    Dalgleish, Angus G.
    Stebbing, Justin
    Adamson, Douglas J. A.
    Arif, Seema Safia
    Bidoli, Paolo
    Chang, David
    Cheeseman, Sue
    Diaz-Beveridge, Robert
    Fernandez-Martos, Carlos
    Glynne-Jones, Rob
    Granetto, Cristina
    Massuti, Bartomeu
    McAdam, Karen
    McDermott, Raymond
    Munoz Martin, Andres J.
    Papamichael, Demetris
    Pazo-Cid, Roberto
    Vieitez, Jose M.
    Zaniboni, Alberto
    Carroll, Kevin J.
    Wagle, Shama
    Gaya, Andrew
    Mudan, Satvinder S.
    BRITISH JOURNAL OF CANCER, 2016, 115 (07) : 789 - 796
  • [34] A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
    Richardson, Gary Edward
    Al-Rajabi, Raed
    Uprety, Dipesh
    Hamid, Anis
    Williamson, Stephen K.
    Baranda, Joaquina
    Mamdani, Hirva
    Lee, Ya-Li
    Li, Li
    Wang, Xingli
    Dong, Xunwei
    CANCERS, 2023, 15 (09)
  • [35] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Fujita, Tomoko
    Sugibayashi, Ko
    Murayama, Kosho
    Yamamoto, Noboru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1795 - 1804
  • [36] ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).
    Grivas, Petros
    Vogelzang, Nicholas J.
    Alva, Ajjai Shivaram
    Feyerabend, Susan
    Loriot, Yohann
    Necchi, Andrea
    Gupta, Sumati
    Josephs, Debra Hannah
    Rodriguez-Vida, Alejo
    Srinivas, Sandy
    Zakharia, Yousef
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Simmons, Andrew
    Nepert, Dale L.
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [37] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Nobuaki Matsubara
    Shota Kusuhara
    Noboru Yamamoto
    Kazuki Sudo
    Masahiko Yanagita
    Kosho Murayama
    Hisashi Kawasumi
    Deanna L. Russell
    Da Yin
    Toshio Shimizu
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 341 - 352
  • [38] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Shunsuke Kondo
    Satoru Iwasa
    Takafumi Koyama
    Tomoko Fujita
    Ko Sugibayashi
    Kosho Murayama
    Noboru Yamamoto
    International Journal of Clinical Oncology, 2022, 27 : 1795 - 1804
  • [39] A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer
    Haddad, R. I.
    Krebs, A. D.
    Vasselli, J.
    Paz-Ares, L. G.
    Robinson, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Phase II, prospective, open-label study of a weekly schedule of irinotecan in patients with advanced colorectal cancer.
    Casinello, J
    Dorta, J
    Aguiar, J
    Pérez-Carrión, J
    Castellanos, J
    Valladares, J
    Sevilla, J
    Belón, J
    Fernández, J
    Casal, J
    ANNALS OF ONCOLOGY, 2000, 11 : 46 - 46
12345